SS-31

SS-31, known in clinical development as elamipretide and earlier as MTP-131 or Bendavia, is a small synthetic peptide built to concentrate inside mitochondria, the structures that generate most of a cell's usable energy. It's one of the more precisely understood compounds in this whole space. In September 2025 it became the first mitochondria-targeted therapy the FDA has ever approved, under the brand Forzinity, for an ultra-rare pediatric disease called Barth syndrome. Barth syndrome is a rare genetic condition, mostly affecting boys, where a faulty gene disrupts cardiolipin (the same inner-membrane lipid SS-31 binds), which weakens the heart and skeletal muscles and causes deep fatigue. That's not a coincidence. It's close to the cleanest test case there is for what SS-31 is supposed to do, which is stabilize cardiolipin. That approval is narrow, and it matters that you understand how narrow. For the aging, energy, and performance reasons most people come looking for SS-31, the human evidence is early, and in several large trials it hasn't held up. This page is here to give you both halves of that picture honestly.

A four-amino-acid peptide (D-Arg-dimethylTyr-Lys-Phe-NH2) that carries a positive charge and builds up strongly inside mitochondria. It was designed by researchers Hazel Szeto and Peter Schiller, which is where the "SS" comes from, and taken through clinical trials by Stealth BioTherapeutics as elamipretide. Because it targets a basic piece of cell biology rather than one disease pathway, it's been tested across a wide range of conditions. The approved prescription form is Forzinity. The material sold online as a "research compound" is not that approved product.

Where the Biology Gets Interesting

The biological context for SS-31 centers on mitochondrial function, skeletal muscle, and cardiac muscle, the tissues that lean hardest on a steady supply of energy. The connecting thread is cardiolipin, a lipid in the inner mitochondrial membrane that helps hold the energy-producing machinery in shape and that tends to degrade with age and illness. This is a systems-level orientation, not proof that the compound changes those systems in a given person. Mechanism, model data, and human evidence belong in separate lanes, and this page keeps them there.

The Mechanism, Without Overstating It

Mitochondria have an inner membrane rich in a distinctive lipid called cardiolipin, which helps hold the energy-producing machinery in the right shape. Cardiolipin tends to break down with age and in disease, and when it does, energy output falls and cells throw off more reactive byproducts. SS-31 binds to cardiolipin and appears to stabilize that inner-membrane structure. In lab and animal work, that's linked to better-preserved energy production and less oxidative stress. It was first described as an antioxidant, but later research points to the membrane-stabilizing role as the bigger part of the story. Here's the framing that matters, though: a well-understood mechanism is not the same thing as a proven benefit in people. SS-31 is actually a textbook example of that gap.

A few things shape how much weight to put on the positive findings. The approval rests on an intermediate endpoint and may hinge on a confirmatory trial. The strongest human signals come from tiny samples, since Barth syndrome affects roughly 150 people in the US and the aging study tested just 39, and only once rather than over time. Several of the larger, better-powered trials simply didn't work. And there's a "right patient" pattern in the data, where the compound seems to help most when the energy machinery is intact but its membrane environment is damaged, and less when the machinery itself is broken. None of this is settled science.

In the trials run so far, the most commonly reported issue was reactions at the injection site, generally mild to moderate, and the compound has been described as well tolerated in those studies. Keep in mind that this safety data comes from monitored clinical settings using the pharmaceutical-grade drug, not from unregulated research-chemical versions of unknown quality. Nothing on this page is medical advice.

Athlete context matters here, and in an unusual way. SS-31 is not on the WADA Prohibited List for 2026, because section S0 turns on approval status and elamipretide gained approval in September 2025. That is a narrow technical point about the approved product, not a clearance for what is sold online: research-grade material remains an unapproved product even though the substance now has an approval.

SS-31 reaches performance and longevity conversations because mitochondrial energy output sits underneath endurance, recovery, and how people feel day to day. That interest is understandable, but the compound should not be read as a performance or anti-aging tool. Its one approval is for a single rare disease, and the aging-and-energy human work so far is early, small, and mixed. The most useful role for this page is orientation: it explains why SS-31 shows up in these discussions and why early findings deserve restraint rather than excitement.

Not a proven energy or anti-aging treatment. The one thing SS-31 is approved for is a single ultra-rare genetic disease.

Not what that approval implies about anything else. Being approved for a single ultra-rare genetic disease says nothing about fatigue, athletic recovery, longevity, or general "mitochondrial health."

Not the FDA-approved prescription product when sold as a research compound. The research-compound version has not been through the same quality controls.

Not a guide to getting or using it. Nothing here describes how to get SS-31 or how to use it, and nothing here is a nudge to do either.

We find SS-31 genuinely interesting, partly because the biology underneath it is so clear, and partly because it's an honest lesson in how a real mechanism doesn't automatically turn into a real-world benefit. The most useful thing we can do is show you the whole thing: the elegant science, the first-ever approval in its class, and the run of large trials that fell short. If you take one idea from this page, make it this. "Well understood" and "proven for what I want" are two different things, and SS-31 sits right on the line between them.